Business Wire

Altium Achieves SOC 2 Type 2, Reinforcing Commitment to Data Security and Compliance

25.5.2023 22:16:00 CEST | Business Wire | Press Release

Share

Altium, LLC (ASX: ALU), the global leader in PCB design software, announces the successful completion of the Service Organization Control (SOC) 2 Type 2 certification. This significant milestone highlights Altium's dedication to maintaining the highest data security and integrity standards within its cloud-based Altium 365 platform.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230525005790/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

SOC 2 Type 2 certification underscores Altium's commitment to ensuring data availability, security, and privacy on the Altium 365 collaborative platform for electronics design. (Graphic: Altium LLC)

Completing the examination and the subsequent report receipt verifies that Altium meets or exceeds the rigorous security measures and industry standards outlined by the American Institute of Certified Public Accountants (AICPA) regarding security, availability, and confidentiality.

The Altium 365 Cloud Security team, under the leadership of Volodymyr Volotko, Director of Cloud Solutions, possesses a wealth of expertise in creating secure and compliant environments for Altium 365 customers.

"By successfully completing the SOC 2 Type 2 examination, we demonstrate our commitment to upholding the highest security standards," said Greg Bellasis, Director of Cybersecurity. "Through implementing effective controls, we can confidently assure our customers that their trust in Altium is well-placed."

Following the completion of the SOC 2 Type 1 audit in March 2022, Altium voluntarily pursued the next level of examination, the SOC 2 Type 2. It's important to note that SOC 2 Type 1 assesses the design of security processes at a specific point in time. In contrast, a Type 2 report evaluates the effectiveness of those controls over a specified period of time. The Type 1 examination establishes the foundation of well-designed controls, while the Type 2 examination provides evidence of the controls' effectiveness and ability to operate consistently over time.

Altium plans to participate in annual assessments to maintain active SOC 2 Type 2 reports, further reinforcing its ongoing data security and compliance commitment.

"Altium's achievement of SOC 2 Type 2, our recent AWS GovCloud offering, and continued progress reaffirm our commitment to delivering the highest levels of security, privacy, and continuity to our clients," stated Nikolay Ponomarenko, Head of Altium 365 Cloud Platform. "We consistently enhance our data management practices, fostering transparency, open communication, and accountability between our customers and ourselves, continuing to invest towards security."

Altium provides a comprehensive Trust Center equipped with a knowledge base to assist users in comprehending the security and compliance features of Altium 365. Further information about SOC 2 and other compliance-related topics can be found by visiting the Altium 365 Trust Center at altium.com/trust.

About Altium:

Altium, LLC (ASX: ALU) is a global software company headquartered in San Diego, California, who are accelerating the pace of innovation through electronics. For over 30 years, Altium has been delivering software that maximizes the productivity of PCB designers and electrical engineers. From individual inventors to multinational corporations, more PCB designers and engineers choose Altium software to design and realize electronics-based products.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Renata Lang
Product Marketing Manager, Altium LLC
renata.lang@altium.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press Release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press Release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press Release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press Release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye